All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study

Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia

(2016) Héléna Boutzen et al.   JOURNAL OF EXPERIMENTAL MEDICINE

RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features

(2016) V I Gaidzik et al.   LEUKEMIA

Targeted Therapy Alone for Acute Promyelocytic Leukemia

(2016) Francesco Lo-Coco et al.   NEW ENGLAND JOURNAL OF MEDICINE

Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells

(2015) M. P. Martelli et al.   BLOOD

Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells

(2015) H. El Hajj et al.   BLOOD

ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group

(2015) P. Paschka et al.   HAEMATOLOGICA

ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group

(2015) P. Paschka et al.   HAEMATOLOGICA

Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients

(2014) M. Tassara et al.   BLOOD

Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)

(2013) V. I. Gaidzik et al.   BLOOD

Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

(2013) Francesco Lo-Coco et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acute Myeloid Leukemia (AML): Different Treatment Strategies Versus a Common Standard Arm—Combined Prospective Analysis by the German AML Intergroup

(2012) Thomas Büchner et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1

(2011) R. Balusu et al.   BLOOD

Eliciting Mucosal Immunity

(2011) Wayne I. Lencer et al.   NEW ENGLAND JOURNAL OF MEDICINE

IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication

(2010) Peter Paschka et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A

(2010) Richard F. Schlenk et al.   JOURNAL OF CLINICAL ONCOLOGY

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA

(2009) A. K. Burnett et al.   BLOOD

Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B

(2008) R. F. Schlenk et al.   HAEMATOLOGICA

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Richard F. Schlenk et al.   NEW ENGLAND JOURNAL OF MEDICINE